Rallybio Announces Proof-of-Concept Results and Development Updates for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia

 -- RLYB212 Demonstrated Dose-Dependent, Rapid and Complete Elimination of Transfused HPA-1a Positive Platelets in HPA-1a Negative Subjects --

-- Mean Reduction in Platelet Elimination Half-Life After Subcutaneous Administration of RLYB212 was ≥90% in both RLYB212 Dose Groups, Achieving Proof-of-Concept Criteria --

-- Phase 2 Study in Pregnant Women at Higher Risk of HPA-1a Alloimmunization to be Initiated in 2H 2024 --

-- Phase 1 Multiple Dose Data and Maternal-Fetal Toxicology Data On-track for 4Q 2023 --

-- Company to Host Investor and Analyst Meeting Webcast with Corresponding Slides at 4:00pm ET --

Related Keywords

Germany ,Connecticut ,United States ,New Haven ,German ,Alloimmune Thrombocytopenia ,Christof Geisen ,European Medicines Agency ,German Red Cross Blood Transfusion Service ,Exchange Commission ,Twitter ,Institute Of Transfusion Medicine ,Linkedin ,Clinical Development ,International Society On Thrombosis ,Drug Administration ,Rallybio Corporation Nasdaq ,Rallybio Corporation ,International Society ,Transfusion Medicine ,Development Update ,Natural History Study ,Analyst Meeting ,Neonatal Alloimmune Thrombocytopenia ,Technology Incubation Program ,Quarterly Report ,Markets ,